{"id":"cefazolin-vancomycin","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Hypersensitivity reactions (rash, urticaria)"},{"rate":"5-10%","effect":"Nephrotoxicity"},{"rate":"1-5%","effect":"Ototoxicity"},{"rate":"2-5%","effect":"Phlebitis at injection site"},{"rate":"1-2%","effect":"Nausea/vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin is a first-generation cephalosporin that inhibits cross-linking of peptidoglycan in the bacterial cell wall. Vancomycin is a glycopeptide antibiotic that binds to D-Ala-D-Ala precursors and prevents cell wall synthesis. Together, this combination provides broad-spectrum coverage against gram-positive bacteria and is commonly used for surgical prophylaxis and serious infections.","oneSentence":"Cefazolin and vancomycin are bactericidal antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and D-Ala-D-Ala residues, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:51.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis"},{"name":"Serious gram-positive bacterial infections"},{"name":"Methicillin-resistant Staphylococcus aureus (MRSA) infections"}]},"trialDetails":[{"nctId":"NCT06748144","phase":"PHASE2, PHASE3","title":"IO Vancomycin Spine","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-05","conditions":"Lumbar Fusion Surgery","enrollment":30},{"nctId":"NCT06567808","phase":"PHASE4","title":"Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2026-03-01","conditions":"Infection, Surgical Site","enrollment":38000},{"nctId":"NCT04731025","phase":"PHASE3","title":"Local Antibiotics for Breast Implants","status":"RECRUITING","sponsor":"Mikkel Herly","startDate":"2021-01-27","conditions":"Implant Complication, Implant Infection, Implant Site Infection","enrollment":1003},{"nctId":"NCT07376889","phase":"PHASE4","title":"Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia","status":"NOT_YET_RECRUITING","sponsor":"Intermountain Health Care, Inc.","startDate":"2026-02-01","conditions":"Staphylococcus Aureus Bacteremia","enrollment":2096},{"nctId":"NCT03283878","phase":"PHASE4","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-24","conditions":"Arthropathy of Knee, Antibiotic Prophylaxis","enrollment":1770},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT07283068","phase":"NA","title":"IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02-15","conditions":"Revision Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":"Staphylococcus Aureus Bacteremia","enrollment":8000},{"nctId":"NCT05831774","phase":"PHASE4","title":"IO Vancomycin in TSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-06-01","conditions":"Shoulder Injuries","enrollment":33},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT04399642","phase":"NA","title":"Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2019-07-05","conditions":"Infection","enrollment":1832},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT07072923","phase":"PHASE4","title":"Antibiotic Impregnated Beads in Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2025-09-01","conditions":"Osteomyelitis of the Foot, Antibiotic Impregnated Beads, Osteomyelitis of Lower Extremities","enrollment":100},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06640491","phase":"PHASE1, PHASE2","title":"Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-15","conditions":"Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT02285140","phase":"NA","title":"Prevention of Infections in Cardiac Surgery","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2015-04","conditions":"Thoracic Surgery, Antibiotic Prophylaxis","enrollment":5989},{"nctId":"NCT03402945","phase":"PHASE4","title":"Prevention of Infections in Cardiac Surgery (PICS) Prevena Study","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-03-05","conditions":"Surgical Site Infections","enrollment":4107},{"nctId":"NCT06814223","phase":"PHASE4","title":"Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-10-28","conditions":"Infection Catheter-Related","enrollment":200},{"nctId":"NCT06384651","phase":"PHASE4","title":"Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-03","conditions":"Infections, Ankle Arthritis","enrollment":40},{"nctId":"NCT05849090","phase":"EARLY_PHASE1","title":"Vancomycin and Tobramycin Powder Use in Acute Open Fractures","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-27","conditions":"Infections","enrollment":10},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Staphylococcal Bacteraemia","enrollment":200},{"nctId":"NCT05959603","phase":"PHASE3","title":"Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2020-05-31","conditions":"Infection","enrollment":363},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT05971537","phase":"PHASE4","title":"Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","status":"RECRUITING","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2023-06-15","conditions":"Peritoneal Dialysis-associated Peritonitis","enrollment":46},{"nctId":"NCT06189885","phase":"NA","title":"Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-08-01","conditions":"Periprosthetic Joint Infection","enrollment":184},{"nctId":"NCT02497365","phase":"NA","title":"Besifloxacin in Bacterial Keratitis","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-09","conditions":"Bacterial Keratitis","enrollment":32},{"nctId":"NCT03426761","phase":"PHASE4","title":"Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections","status":"COMPLETED","sponsor":"Infectious Diseases Physicians, Inc.","startDate":"2018-01-25","conditions":"Bone Infection, Osteomyelitis, Septic Arthritis","enrollment":41},{"nctId":"NCT05705843","phase":"PHASE4","title":"IO vs IV Vancomycin in Tourniquetless TKA","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-25","conditions":"Infection, Surgical Site","enrollment":40},{"nctId":"NCT05606302","phase":"","title":"A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-10-01","conditions":"Drug-specific Antibodies","enrollment":14000},{"nctId":"NCT00634166","phase":"PHASE4","title":"Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group","status":"TERMINATED","sponsor":"Mylan Inc.","startDate":"2007-09","conditions":"Burns","enrollment":220},{"nctId":"NCT05297513","phase":"PHASE4","title":"Efficacy of ActiveMatrix on Spinal SSI Rate","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-07","conditions":"Spinal Stenosis Lumbar, Surgical Site Infection, Back Pain Lower Back Chronic","enrollment":275},{"nctId":"NCT03432858","phase":"PHASE4","title":"Preoperative Antibiotics for Carpal Tunnel Release Surgery","status":"COMPLETED","sponsor":"WellSpan Health","startDate":"2018-05-17","conditions":"Carpal Tunnel Syndrome","enrollment":184},{"nctId":"NCT02216227","phase":"NA","title":"Checklist to Prevent MRSA Surgical Site Infections","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-04-01","conditions":"Surgical Site Infection","enrollment":1794},{"nctId":"NCT01792804","phase":"PHASE3","title":"Staphylococcus Aureus Bacteremia Antibiotic Treatment Options","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2013-12","conditions":"Staphylococcus Aureus Infection","enrollment":215},{"nctId":"NCT00967941","phase":"","title":"Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis","status":"COMPLETED","sponsor":"CAMC Health System","startDate":"2007-08","conditions":"MRSA Infections","enrollment":169},{"nctId":"NCT02208063","phase":"PHASE3","title":"A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial","status":"TERMINATED","sponsor":"Cumberland Pharmaceuticals","startDate":"2014-12","conditions":"Bacteremia","enrollment":121},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT01628666","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-12","conditions":"Arrhythmia","enrollment":12814},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT02365493","phase":"PHASE3","title":"Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection","status":"TERMINATED","sponsor":"Menzies School of Health Research","startDate":"2015-08-26","conditions":"Methicillin-Resistant Staphylococcus Aureus","enrollment":358},{"nctId":"NCT02007018","phase":"NA","title":"Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2015-01-01","conditions":"Postoperative Surgical Site Infections","enrollment":300},{"nctId":"NCT01458223","phase":"PHASE4","title":"The Effect of Prolonged Postoperative Antibiotics Administration on Rate of Infection in Patients Undergoing Posterior Spine Surgery Requiring a Hemovac Drain","status":"COMPLETED","sponsor":"The London Spine Centre","startDate":"2011-10","conditions":"Postoperative Infection","enrollment":645},{"nctId":"NCT02027532","phase":"NA","title":"Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin","status":"TERMINATED","sponsor":"University of Tennessee","startDate":"2009-10","conditions":"Infection, Closed Fractures","enrollment":430},{"nctId":"NCT01619982","phase":"PHASE4","title":"Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-02","conditions":"Congenital Heart Diseases, Aortic Valve Disorder","enrollment":32},{"nctId":"NCT03466645","phase":"PHASE1, PHASE2","title":"The Effectiveness of Vancomycin in Comarison With Cefazolin in Prevention of SSI After Craniotomy","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2018-04-01","conditions":"Elective Craniotomy-candidated Patients","enrollment":126},{"nctId":"NCT01191840","phase":"PHASE2","title":"Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection","status":"COMPLETED","sponsor":"Duke University","startDate":"2011-02","conditions":"Bacteremia","enrollment":509},{"nctId":"NCT00818766","phase":"NA","title":"Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-03","conditions":"Antibiotic Prophylaxis","enrollment":251},{"nctId":"NCT02344511","phase":"PHASE3","title":"Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","startDate":"2016-03","conditions":"Osteomyelitis","enrollment":""},{"nctId":"NCT02413034","phase":"NA","title":"The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2013-11","conditions":"Prosthetic Joint Infection","enrollment":28},{"nctId":"NCT02307006","phase":"PHASE4","title":"The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2015-01","conditions":"Surgical Site Infection","enrollment":500},{"nctId":"NCT01400867","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Infections, Pediatrics","enrollment":163},{"nctId":"NCT01613092","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2011-05","conditions":"Arrhythmia","enrollment":241},{"nctId":"NCT01867138","phase":"PHASE3","title":"Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2007-03","conditions":"Nosocomial Neonatal Sepsis","enrollment":109},{"nctId":"NCT01612052","phase":"PHASE4","title":"Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2011-05","conditions":"MRSA - Methicillin Resistant Staphylococcus Aureus Infection","enrollment":200},{"nctId":"NCT01174212","phase":"PHASE4","title":"Effect of Prophylactic Antibiotics on Intra-Operative Culture Results","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-07","conditions":"Infection, Arthroplasty","enrollment":65},{"nctId":"NCT00108433","phase":"PHASE3","title":"Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections","status":"TERMINATED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Bacteremia, Gram-Positive Bacterial Infections","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ancef","Vancin"],"phase":"marketed","status":"active","brandName":"Cefazolin / Vancomycin","genericName":"Cefazolin / Vancomycin","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefazolin and vancomycin are bactericidal antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and D-Ala-D-Ala residues, respectively. Used for Surgical site infection prophylaxis, Serious gram-positive bacterial infections, Methicillin-resistant Staphylococcus aureus (MRSA) infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}